GlassScriptPhysician profile
James W Price
NPI 1780640110
$941.96
in general payments reported to CMS, 2019-2025
22 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.33 · 2021: $13.67 · 2022: $133 · 2023: $138 · 2024: $306 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $165.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $95.71 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $72.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $71.85 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $56.69 | 2022-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.57 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $50.03 | 2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $45.63 | 2022-2024 | Jardiance, Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $45.52 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $42.92 | 2023-2024 | |
| Stryker Corporation | $36.37 | 2025 | Revcore Thrombectomy Catheter |
| Biogen, INC. | $34.41 | 2025 | Skyclarys |
| Sumitomo Pharma America, INC. | $21.79 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.51 | 2023 | Xifaxan |
| Abbvie INC. | $19.32 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.53 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $17.95 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $17.65 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2025 | |
| Vanda Pharmaceuticals INC. | $14.81 | 2025 | Fanapt, Hetlioz |
| Ardelyx, INC. | $13.13 | 2024 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.